Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 8, 2006, Pages 2043-2050

  Canfield, Steven E ^a,b   Zhu, Keyi ^a   Williams, Simon A ^a,c   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BORTEZOMIB; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; OLOMOUCINE; PHOSPHOTRANSFERASE; PROTEIN P21; ROSCOVITINE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CDC2 PROTEIN KINASE; CELL DIVISION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRAZINES; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 33748369901     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0437     Document Type: Article

References (55)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003;30:219-26.
3. Dreicer R, Klein EA. Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. Semin Oncol 2001;28:45-8.
4. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001;28:40-4.
5. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5:417-21.
6. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Mad 2003;348: 2609-17.
8. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
9. Pink MM, Pien CS, Worland P, et al. PS-341 enhances chemotherapeutic effects in human xenograph models. Proc Am Assoc Cancer Res 2002;43:158.
10. Gumerlock PH, Moisan LP, Lau AH, et al. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin Cancer Res 2001;7:157.
11. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
12. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
13. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3: 59-70.
14. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003;2:835-43.
15. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
16. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxolinduced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
17. Kamat AM, Karashima T, Davis DW, et al, The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-90.
18. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003;63:7338-44.
19. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20:4188-97.
20. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
21. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20:31-5.
22. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997;24: S15-72-7.
23. Smith DC, Pienta KJ. Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999;26:109-11.
24. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003; 170:1709-16.
25. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Huntingt) 2002;16:63-72.
26. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15:525-45.
27. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42.
28. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003;61:774-80.
29. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18:1050-7.
30. Herbst RS, Khuri FR. Mode of action of docetaxel-a basis for combination with novel anticancer agents. Cancer Treat Rev 2003;29:407-15.
31. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:27-36.
32. Kuzur ME AK, Huntington MO, et al. A phase II trial of docetaxel and herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 2000;19:512.
33. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel (D) and herceptin (H) as first-or second-line treatment in HER-2 overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:1949.
34. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
35. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001;21:1301-5.
36. Piccart MJ, Branie F, de Valeriola M, et al. A phase I, clinical and pharmacolkinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patient (PTS) with solid tumors. Proc Am Soc Clin Oncol 2001;20:318.
37. Tolcher AW, Kuhn J, Schwartz G, et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004;10:5048-57.
38. Morris MJ, Tong WP, Cordon-Cardo C, et al. BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. Eur J Cancer 2001;37:218.
39. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB: NFκB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-9.
40. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
41. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003;2:694-9.
42. Lee C, Waldman T. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341. Cancer Biol Ther 2003;2:700-1.
43. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
44. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
45. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005;65:4902-8.
46. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
47. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
48. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10: 3839-52.
49. Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res 2004;295:555-66.
50. Fribley A, Zang Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
51. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
52. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
53. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
54. Nawrocki ST, Carew JS, Dunner K, Jr., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
55. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 2003;9:955-60.